Vanda Pharmaceuticals Inc — Cash Flow (NASDAQ:VNDA) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Cash from operating activities 51.77 M64.21 M31.98 M12.8 M-15.76 M-109.44 M -109.44 M Cash from investing activities -41.5 M-76.7 M49.92 M-12.06 M-17.43 M94.86 M 94.86 M Cash from financing activities 5.63 M3.55 M734 K0-155 K-2.91 M -2.91 M Free cash flow 49.98 M63.66 M31.3 M12.42 M-16.25 M-110.44 M -110.44 M

ニュース

FDAがVandaの希少皮膚疾患治療薬imsidolimabの申請を受理

Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug - Vanda Pharmaceuticals (NASDAQ:VNDA)

American Express, Oracle among market cap stock movers on Monday

H.C. WainwrightがFDA承認を受けてVanda Pharmaceuticalsの目標株価を24ドルに引き上げ

Vanda Pharmaceuticals stock price target raised to $24 by H.C. Wainwright on FDA approval

Why Is Vanda Pharmaceuticals Stock Soaring On Monday? - Vanda Pharmaceuticals (NASDAQ:VNDA)

Stock Market Today: Dow Jones, S&P 500 Futures Drop After Supreme Court Strikes Down Trump's Emergency Tariffs— Novo Nordisk, Strategy, Vanda In Focus - State Street SPDR S&P 500 ETF Trust (ARCA:SPY)

FDAがVanda PharmaceuticalsのBipolar I治療薬を承認し、同社株が急騰

Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug

VandaのBysanti、双極性障害および統合失調症の治療薬としてFDAが承認

FDA approves Vanda’s Bysanti for bipolar disorder, schizophrenia

Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript